Literature DB >> 11992619

Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.

Gero Kramer1, Georg E Steiner, Alessandra Handisurya, Ursula Stix, Andrea Haitel, Birgit Knerer, Alois Gessl, Chung Lee, Michael Marberger.   

Abstract

BACKGROUND: Benign prostatic hyperplasia (BPH) frequently exhibit infiltration of CD4 (+)/CD45RO (+) memory-T-lymphocytes. Expression and impact of lymphocyte-derived growth factors on prostatic stromal cell (PSC) growth were investigated. METHODS; Lymphokine synthesis in normal prostate tissues (n = 3), BPH-tissues (n = 13), BPH-derived T-cells (n = 6), BPH-derived epithelial cells (BPH-EC) (n = 5), normal prostate-derived (n = 3) and BPH-derived stromal cell lines (BPH-SC) (n = 6), and prostate cancer (CaP) lines (n = 3) was analyzed by RT-PCR and Southern-blotting. The effect of interleukin (IL)-2, -4, -7, and interferon-gamma (IFN-gamma) on normal and BPH-SC growth was investigated by (3)H-thymidine incorporation assays.
RESULTS: All BPH-tissues and, to a lesser degree, normal prostates, expressed significant amounts of IFN-gamma mRNA. However, only BPH-tissues contained IL-2 and IL-4 mRNA (ratio: 10:13). BPH-T-cell lines were heterogeneous in composition and expressed significant amounts of IFN-gamma, IL-2, and IL-4 mRNA. Low level expression of these lymphokines was also observed in BPH-EC, CaP lines, and PSC lines. IL-2, -7 and IFN-gamma stimulated the proliferation of BPH-PSC lines but not that of normal PSC, while IL-4 inhibited BPH-PSC growth.
CONCLUSIONS: Chronic inflammation may induce an increased growth pattern of fibromuscular tissue in BPH similar to that of wound healing. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992619     DOI: 10.1002/pros.10084

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  61 in total

Review 1.  Immune mediators of chronic pelvic pain syndrome.

Authors:  Stephen F Murphy; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Nat Rev Urol       Date:  2014-04-01       Impact factor: 14.432

2.  Advances in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: highlights from the 21st European association of urology congress, april 5-8, 2006, paris, france.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2006

3.  The picture of the prostatic lymphokine network is becoming increasingly complex.

Authors:  Georg E Steiner; Bob Djavan; Gero Kramer; Alessandra Handisurya; Martin Newman; Chung Lee; Michael Marberger
Journal:  Rev Urol       Date:  2002

4.  [Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].

Authors:  G Kramer; D Mitteregger; A Maj-Hes; S Sevchenco; W Brozek
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 5.  Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.

Authors:  Vatsal Mehta; Chad M Vezina
Journal:  Differentiation       Date:  2011 Nov-Dec       Impact factor: 3.880

6.  Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation.

Authors:  Eugene V Vykhovanets; Sanjeev Shukla; Gregory T MacLennan; Olena V Vykhovanets; Donald R Bodner; Sanjay Gupta
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

7.  The senescence-associated secretory phenotype promotes benign prostatic hyperplasia.

Authors:  Paz Vital; Patricia Castro; Susan Tsang; Michael Ittmann
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

8.  Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Authors:  Kazutoshi Fujita; Charles M Ewing; Robert H Getzenberg; J Kellogg Parsons; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

9.  A signaling network in phenylephrine-induced benign prostatic hyperplasia.

Authors:  Jayoung Kim; Yutaka Yanagihara; Tadahiko Kikugawa; Mihee Ji; Nozomu Tanji; Yokoyama Masayoshi; Michael R Freeman
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

10.  Etiopathogenesis of benign prostatic hypeprlasia.

Authors:  Jie Tang; Jingchun Yang
Journal:  Indian J Urol       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.